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Abstract
Background: Careful characterization of the phenotype and genotype of Huntington disease (HD) can foster better
understanding of the condition.
Methods: We conducted a cohort study in the United States, Canada, and Australia of members of families affected by HD.
We collected demographic and clinical data, conducted the Unified Huntington’s Disease Rating Scale and Mini-Mental
State Examination, and determined Huntingtin trinucleotide CAG repeat length. We report primarily on cross-sectional
baseline data from this recently completed prospective, longitudinal, observational study.
Results: As of December 31, 2009, 2,318 individuals enrolled; of these, 1,985 (85.6%) were classified into six analysis groups.
Three groups had expanded CAG alleles (36 repeats or more): individuals with clinically diagnosed HD [n=930], and
clinically unaffected first-degree relatives who had previously pursued [n=248] or not pursued [n=112] predictive DNA
testing. Three groups lacked expanded alleles: first-degree relatives who had previously pursued [n=41] or not pursued
[n=224] genetic testing, and spouses and caregivers [n=430]. Baseline mean performance differed across groups in all
motor, behavioral, cognitive, and functional measures (p,0.001). Clinically unaffected individuals with expanded alleles
weighed less (76.0 vs. 79.6 kg; p=0.01) and had lower cognitive scores (28.5 vs. 29.1 on the Mini Mental State Examination;
p=0.008) than individuals without expanded alleles. The frequency of ‘‘high normal’’ repeat lengths (27 to 35) was 2.5% and
repeat lengths associated with reduced penetrance (36 to 39) was 2.7%.
Conclusion: Baseline analysis of COHORT study participants revealed differences that emerge prior to clinical diagnosis.
Longitudinal investigation of this cohort will further characterize the natural history of HD and genetic and biological modifiers.
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Introduction
Huntington disease (HD) is an autosomal dominant neurode-
generative disorder resulting from an unstable expansion of a
cytosine-adenine-guanine (CAG) trinucleotide repeat in the
Huntingtin gene [1]. The CAG repeat length normally varies from
6 to 35 CAG units. Repeat lengths from 27 to 35 are considered
‘‘high normal’’ and may expand in subsequent generations [2–4].
Repeat lengths from 36 to 39 exhibit reduced penetrance, with
disease manifestations occurring at a later age or not at all [3–5].
Alleles with forty or more repeats are fully penetrant and
inevitably associated with neuronal degeneration and the progres-
sive motor, cognitive, and behavioral features of HD [6]. Although
longer CAG repeat expansions are associated with earlier disease
manifestation [7–9], age of onset varies considerably for any given
CAG repeat expansion [10].
The prevalence of HD is approximately 1 per 10,000 individuals,
with a significant population at risk for the disease [11–12]. Improved
understanding of and treatments for HD may, therefore, benefit not
only those with manifest disease but also asymptomatic individuals
who carry an expanded allele. Few treatments are available that
specifically target HD, and no therapies currently prevent or delay
disease onset or progression. We, therefore, conducted a cohort study
of affected, unaffected, at-risk, and not at-risk individuals from the
HD community to characterize the natural history of HD by
collecting clinical data and biological samples to enhance the design
of future clinical trials aimed at reducing the burden of HD. We
report the baseline characteristics of the study population.
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The protocol for this trial and is available as supporting
information; see Protocol S1
Study design
The Cooperative Huntington Observational Research Trial
(COHORT) is an observational study designed to collect
phenotypic data and biological samples from individuals with
HD and their family members.
Setting
Beginning on February 14, 2006, investigators at 44 sites in the
UnitedStates(n=38), Canada(n=4),and Australia(n=2)enrolled
research participants. We report baseline data collected through
December 31, 2009. The study was concluded on June 30, 2011.
Participants
Eligible research participants were from four groups: (1)
individuals with clinically diagnosed HD, (2) individuals who
pursued genetic testing prior to baseline, carry an expanded allele,
but did not have clinically diagnosed HD; (3) first-degree or
second-degree relatives of individuals in the first two groups; and
(4) spouses or caregivers of individuals enrolled from group one or
two. Individuals under 18 years could only enroll if they were
clinically diagnosed with HD.
Ethics
The institutional review board of the University of Rochester
and each site approved the protocol. All study participants
provided written informed consent, or, if unable had an
authorized representative provide consent on their behalf.
Participants agreed to baseline and annual evaluations for an
indefinite time period with no predetermined limit on the sample
size. To protect the confidentiality and data of participants, all
were assigned a unique identification number without identifying
information.
Outcomes
At baseline, a site investigator and coordinator obtained
demographic and clinical data, performed a complete physical
and neurological exam, including the Unified Huntington’s Disease
Rating Scale (UHDRS) [13] and Mini Mental State Examination
(MMSE) [14], and collected a blood sample for DNA isolation and
for establishing an optional transformed lymphoblastoid cell line. At
follow-up visits, new clinical events and current medications were
recorded and an examination, including the UHDRS and the
MMSE, was performed. Individuals reporting scores above a pre-
specified threshold for depressed mood or suicidal ideation were
referred to a mental health professional.
Huntingtin CAG repeat genotyping
The Huntingtin CAG repeat size was determined by polymerase
chain reaction amplification, using genomic DNA extracted from
blood and, if provided, lymphoblastoid cell lines [15]. All genotyping
was performed at a single site (Center for Human Genetic Research,
Massachusetts General Hospital, Boston, Massachusetts). Alleles with
36 or more repeats were considered expanded. Individual genotypes
remained anonymous and were not communicated to any party.
Reportable events
To promote the safety of participants, a clinical monitor and an
independent event monitoring committee evaluated reportable
events, including suicides, suicide attempts, deaths other than
suicides, and premature withdrawals.
Optional assessments
Participants had the option to provide blood to generate a
lymphoblastoid cell line for future research, to be informed of
clinical trials, and to complete a baseline Family History
Questionnaire (which is not included in this report) that was
updated annually to track births, deaths, and HD diagnoses.
Statistical methods
Based on prior genetic testing results, Huntingtin genotyping, and
baseline clinical diagnosis, participants were classified into six
groups. An affirmative response to UHDRS question 80, ‘‘Based
on the entire UHDRS, do you believe with a confidence level
$99% that this subject has manifest HD?’’ classified the individual
as having clinically diagnosed HD.
Three groups had an expanded allele: individuals with clinically
diagnosed HD, first-degree relatives who had pursued genetic
testing, and first-degree relatives who had not pursued genetic
testing. Three groups did not have an expanded allele: first-degree
relatives who had pursued genetic testing, first-degree relatives
who had not pursued genetic testing, and spouses and caregivers.
Participants’ demographic, clinical, and genetic characteristics
were compared across the six groups using descriptive statistics.
For each characteristic, an overall test of heterogeneity of means
or proportions was performed. To provide some protection against
multiplicity effects, additional comparisons were restricted to those
characteristics for which the overall test was significant. For these
characteristics, additional testing was limited to six comparisons:
(1) clinically diagnosed HD vs. all other groups; (2) clinically
diagnosed HD vs. relatives with expanded alleles; (3) clinically
diagnosed HD vs. spouses and caregivers; (4) relatives with an
expanded allele who had pursued genetic testing vs. those who had
not pursued genetic testing; (5) relatives with expanded alleles vs.
relatives without an expanded allele; and (6) relatives without an
expanded allele who had not pursued genetic testing vs. those that
had pursued genetic testing. Continuous outcomes, adjusted for
age and gender, were compared using analysis of covariance
models that were used to conduct overall tests of heterogeneity of
means, estimate contrasts of the group means, and evaluate the six
comparisons. Categorical outcomes were compared using chi-
square or Fisher’s exact tests. Hypothesis testing was conducted at
the two-sided significance level of 5%.
Results
Participants
Between February 14, 2006 and December 31, 2009, 2,318
participants enrolled in the COHORT study. Data from 333
(14.4%) participants were excluded from this analysis for the
following reasons: 288 had incomplete genotypic data (e.g.,
absence of CAG repeat length data), 32 had inconsistent genotypic
and clinical data (e.g., spouse or caregiver with an expanded CAG
allele), seven were second-degree relatives excluded due to low
enrollment, and six were missing data necessary for classification
of an individual into a group [Figure 1].
Demographic characteristics and medical history
The 1985 participants in this analysis (Tables 1,2,3) were
primarily female (56.3%), had completed at least 12 years of
education at the time of enrollment (90.0%), but were not
currently employed in the labor force (55.3%).
COHORT Study
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Table 1. Baseline demographics of the COHORT population by group.
Groups that carry an expanded allele Groups that do not carry an expanded allele
Individuals
with clinically
diagnosed
HD
[n=930]
First-degree
relatives who
pursued genetic
testing and carry
an expanded
allele
[n=248]
First-degree
relatives who did
not pursue genetic
testing and carry
an expanded
allele
[n=112]
First-degree
relatives who did
not pursue genetic
testing and do not
carry an expanded
allele
[n=224]
First-degree
relatives who
pursued genetic
testing and do
not carry an
expanded allele
[n=41]
Spouses
and
caregivers
[n=430] P-value*
Group definition
(CAG)n of 36 or greater Yes Yes Yes No No No -
Genetic testing pursued
prior to baseline
Some Yes No No Yes No -
Clinically diagnosed
with HD
Y e s N o N oN oN o N o -
Demographics
Age [years] 51.9 (12.0) 40.9 (12.5) 40.9 (12.9) 47.2 (14.3) 43.9 (12.2) 52.4 (12.3) ,0.001
Female [%] 51.6 64.1 61.6 69.2 61.0 53.5 ,0.001
White [%] 93.2 96.0 90.2 91.0 97.6 94.2 0.11
Ethnicity [% reporting
Spanish origin]
3.9 4.4 1.8 4.5 4.9 4.7 0.82
Education [% completing
high school or more]
89.4 90.7 88.4 93.7 73.2 90.7 0.004
Employment status [%
currently in labor force]
16.8 68.6 72.3 74.4 65.9 66.5 ,0.001
Marital status
[% currently married]
60.2 62.1 56.3 60.1 61.0 89.5 ,0.001
Values are listed as mean (standard deviation) unless otherwise noted.
COHORT=Cooperative Huntington Observational Research Trial; HD=Huntington disease; (CAG)n=cytosine-adenine-guanine repeat length in the Huntingtin allele;
UHDRS=Unified Huntington’s Disease Rating Scale.
*P-values refer to overall tests of heterogeneity across all six groups.
doi:10.1371/journal.pone.0029522.t001
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one prior suicide attempt. Individuals with clinically diagnosed
HD were more likely to have attempted suicide (7.1%) than
caregivers or spouses (1.2%; p,0.001) and all other study
participants (2.7%; p,0.001). The most commonly used medica-
tions among those with clinically diagnosed HD were anti-
depressants (32.4%), multivitamins (27.4%) and anti-psychotics
(24.5%) and for all other groups were multivitamins (27.4%), lipid
modifying agents (18.9%), and anti-depressants (11.5%) (Table 4).
Clinical characteristics
Weight and body mass index varied significantly across groups.
Individuals with clinically diagnosed HD weighed less (74.0 kg)
than spouses and caregivers (83.6 kg; p,0.001) and had a lower
body mass index (25.4 kg/m
2 vs. 29.1 kg/m
2;p ,0.001). First-
degree relatives who carried an expanded allele but were not
clinically diagnosed with HD weighed less (76.0 kg vs. 79.6 kg;
p=0.01) and tended to have a lower body mass index (26.5 kg/m
2
vs. 27.8 kg/m
2; p=0.06) than first-degree relatives without an
expanded allele.
Motor, behavioral, cognitive, and functional scores on the
UHDRS differed across groups, as those with clinically diagnosed
HD had worse scores than all other participants (p,0.001 for all
aspects of the UHDRS). Similarly, MMSE scores differed
significantly across groups, and those with clinically diagnosed
HD had worse scores (25.0) than spouses and caregivers (29.1;
P,0.001). First-degree relatives with expanded alleles who were
not clinically diagnosed with HD had lower MMSE scores (28.5)
than all first-degree relatives without an expanded allele (29.1;
p=0.008).
Distribution of CAG repeat lengths
Table 5 and 6 show the distribution of participants’ CAG
repeat lengths for the larger and shorter Huntingtin alleles. Fifty
individuals (2.5%) had a repeat length on their larger allele in the
high normal range, and none had clinically diagnosed HD. Fifty-
three individuals (2.7%) had CAG repeat lengths on their larger
allele associated with reduced penetrance. Of these, 15 (28.3%)
were diagnosed with HD prior to their baseline visit.
The average CAG repeat length of the larger allele was
44.264.1 for individuals with clinically diagnosed HD (range 36 to
100 repeats) and 42.662.8 for first-degree relatives with an
expanded allele (range 38 to 58 repeats) [Figure 2].
Reportable events
Through December 31, 2009, one completed suicide in an
individual with clinically diagnosed HD and eleven suicide
attempts (nine in individuals with clinically diagnosed HD)
occurred (Table 7). The individual who committed suicide had
reported a prior history of depression and multiple previous
Table 2. Baseline clinical characteristics and genetics of the COHORT population by group.
Groups that carry an expanded allele Groups that do not carry an expanded allele
Individuals
with clinically
diagnosed
HD
[n=930]
First-degree
relatives who
pursued
genetic testing
and carry an
expanded
allele
[n=248]
First-degree
relatives who
did not pursue
genetic testing
and carry an
expanded
allele
[n=112]
First-degree
relatives who
did not pursue
genetic testing
and do not
carry an
expanded allele
[n=224]
First-degree
relatives who
pursued genetic
testing and do
not carry an
expanded
allele
[n=41]
Spouses
and caregivers
[n=430] P-value*
Medical history
History of at least one suicide
attempt [%]
7.1 4.8 3.6 1.8 7.3 1.2 ,0.001
Clinical characteristics**
Physical features and vital signs
Height [centimeters] 170.5 (9.9) 169.0 (9.4) 169.1 (10.3) 168.2 (9.8) 171.6 (9.7) 169.3 (10.3) 0.11
Weight [kilograms] 74.0 (16.8) 76.4 (21.7) 75.3 (17.9) 79.4 (21.7) 80.8 (17.8) 83.6 (21.5) ,0.001
Body mass index [kilograms/
meter
2]
25.4 (5.0) 26.6 (6.7) 26.2 (5.3) 27.9 (6.7) 27.3 (4.9) 29.1 (6.5) ,0.001
Pulse [beats/minute] 74.5 (12.3) 72.7 (11.4) 71.0 (10.3) 69.5 (11.2) 71.4 (10.4) 69.7 (10.5) ,0.001
Systolic blood pressure
[millimeters of mercury]
123.6 (17.0) 123.2 (15.3) 123.5 (16.3) 128.3 (17.4) 125.3 (15.4) 129.5 (16.6) ,0.001
Diastolic blood pressure
[millimeters of mercury]
76.1 (10.6) 76.6 (10.2) 76.4 (11.6) 77.5 (10.7) 76.6 (10.0) 78.5 (11.8) 0.002
Genetics
(CAG)n of longer allele 44.2 (4.1) 42.6 (2.8) 42.1 (2.4) 20.0 (3.5) 20.5 (4.2) 20.3 (3.6) ,0.001
(CAG)n of shorter allele{ 18.5 (3.5) 18.8 (3.5) 18.1 (3.0) 18.4 (2.4) 18.8 (2.6) 18.6 (2.3) 0.43
Values are listed as mean (standard deviation) unless otherwise noted.
COHORT=Cooperative Huntington Observational Research Trial; HD=Huntington disease; (CAG)n=cytosine-adenine-guanine repeat length in the Huntingtin allele;
UHDRS=Unified Huntington’s Disease Rating Scale.
*P-values refer to overall tests of heterogeneity across all six groups.
**For motor and behavioral measures, higher scores reflect greater impairment. For cognitive, independence, and functional measures, higher scores reflect less
impairment.
{For participants who do not carry an expanded allele, the (CAG)n of the shorter allele represents the average of two normal alleles.
doi:10.1371/journal.pone.0029522.t002
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suicide, nine (82%) were female, the mean age was 43.4 (range 26–
55), seven (64%) had reported a prior history of depression, and
four (36%) had reported a history of at least one previous suicide
attempt. For those with clinically diagnosed HD, the most
commonly reported cause was disease progression or complica-
tions (n=8), followed by cardiac etiology (n=5) and respiratory
etiology (n=5). The main reasons for premature withdrawal were
voluntary withdrawal of consent (n=20), lost to follow-up (n=11),
and caregiver decision (n=5).
Optional assessments
Participation in the optional assessments was high, as 97% of
participants consented to provide specimens for lymphoblastoid
cell lines, 98% consented to be contacted for future studies, and
70% completed the Family History Questionnaire.
Discussion
In a large, multi-national observational study of individuals
from families affected by HD, the groups enrolled differed in their
demographic, clinical, and genetic features at baseline. While
many differences observed were expected, several are noteworthy.
Consistent with the growing evidence that changes occur in
individuals who carry an expanded allele prior to the clinical
(motor) diagnosis of HD [16], these individuals had worse
cognitive performance on the UHDRS and MMSE and weighed
less than those without expanded alleles. A recent report found
that nearly 40% of individuals who knew they carried an
expanded Huntingtin allele but were not diagnosed with HD met
criteria for mild cognitive impairment [17]. This study also adds
evidence that weight loss may precede the clinical onset of
symptoms [18] and is consistent with HD transgenic mice studies
showing that weight loss precedes motor symptoms [19–20].
Table 3. Baseline motor, behavioral, and cognitive characteristics of the COHORT population by group.
Groups that carry an expanded allele Groups that do not carry an expanded allele
Individuals
with
clinically
diagnosed
HD
[n=930]
First-degree
relatives who
pursued genetic
testing and
carry an
expanded allele
[n=248]
First-degree
relatives who
did not pursue
genetic testing
and carry an
expanded
allele
[n=112]
First-degree
relatives who
did not pursue
genetic testing
and do not carry
an expanded allele
[n=224]
First-degree
relatives who
pursued genetic
testing and do
not carry an
expanded allele
[n=41]
Spouses
and
caregivers
[n=430] P-value*
Motor assessment**
Total UHDRS motor
assessment [0–124]
39.1 (18.3) 6.8 (10.6) 6.9 (11.3) 2.3 (3.3) 1.2 (2.5) 1.5 (2.8) ,0.001
Total maximal chorea
score [0–28]
10.1 (5.0) 1.4 (3.2) 2.0 (4.2) 0.2 (0.6) 0.07 (0.4) 0.03 (0.3) ,0.001
Total maximal dystonia
score [0–20]
3.5 (3.8) 0.4 (1.5) 0.3 (1.2) 0.03 (0.2) 0 (0) 0.02 (0.1) ,0.001
Behavioral assessment
UHDRS Behavioral
frequency [0–44]
7.0 (6.1) 6.9 (6.9) 6.4 (6.2) 4.5 (4.5) 4.9 (4.7) 4.4 (4.2) ,0.001
UHDRS Behavioral
frequency6severity [0–176]
14.0 (15.4) 12.7 (17.7) 11.2 (15.2) 6.5 (9.1) 7.8 (12.5) 6.2 (9.0) ,0.001
Cognitive assessment
Mini Mental State
Examination [0–30]
25.0 (4.6) 28.6 (1.9) 28.2 (2.5) 29.0 (1.6) 29.4 (1.3) 29.1 (1.5) ,0.001
UHDRS Verbal fluency 21.9 (12.5) 38.1 (14.1) 36.6 (14.9) 39.8 (11.7) 42.2 (10.2) 40.1 (12.1) ,0.001
UHDRS Symbol digit
modalities test
23.6 (11.2) 45.4 (12.5) 45.2 (12.4) 49.5 (11.8) 49.2 (10.4) 45.9 (10.2) ,0.001
UHDRS Stroop color naming 44.3 (16.9) 70.9 (17.8) 71.1 (16.0) 76.9 (15.8) 72.8 (14.5) 73.3 (14.8) ,0.001
UHDRS Stroop word reading 58.0 (21.9) 90.1 (21.5) 90.4 (19.2) 95.8 (16.3) 99.2 (17.8) 94.6 (19.3) ,0.001
UHDRS Stroop interference 25.5 (12.5) 42.8 (12.9) 41.2 (12.3) 44.8 (12.0) 50.6 (23.7) 41.8 (12.1) ,0.001
UHDRS Independence
assessment
79.1 (16.2) 97.2 (7.2) 99.1 (3.9) 99.9 (0.9) 99.5 (3.1) 99.8 (1.4) ,0.001
UHDRS Functional
assessment
18.7 (6.0) 24.4 (1.9) 24.8 (1.1) 24.9 (0.3) 24.9 (0.5) 24.9 (1.3) ,0.001
UHDRS Total functional
capacity
8.1 (3.4) 12.3 (1.7) 12.7 (1.0) 12.9 (1.0) 12.9 (0.5) 12.9 (0.6) ,0.001
Values are listed as mean (standard deviation) unless otherwise noted.
COHORT=Cooperative Huntington Observational Research Trial; HD=Huntington disease; (CAG)n=cytosine-adenine-guanine repeat length in the Huntingtin allele;
UHDRS=Unified Huntington’s Disease Rating Scale.
*P-values refer to overall tests of heterogeneity across all six groups.
**For motor and behavioral measures, higher scores reflect greater impairment. For cognitive, independence, and functional measures, higher scores reflect less
impairment.
doi:10.1371/journal.pone.0029522.t003
COHORT Study
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e29522Future longitudinal assessment will more fully characterize the
prodrome of HD.
The results also provide guidance on suicide risks among
individuals from families with HD. Among individuals with HD,
suicide is more common than in the general population [16,21–
24] and accounts for 5 to 7% of deaths [22–23,25]. Over 25% of
individuals with HD attempt suicide at least once [22]. Through
2009 only one suicide occurred in COHORT, and among 930
individuals with clinically diagnosed HD followed for more than
2000 participant-years, only nine suicide attempts occurred. The
rate among individuals in other groups is lower. While the low rate
may be due to low ascertainment, suicides and suicide attempts are
prospectively assessed and reported within three working days
after a site becomes aware of the event. The study’s prospective
annual assessment of mental health and the requirement for
referral to a mental health professional when pre-specified mood
and ideation thresholds are met may be contributing to the
relatively low rates observed. Another factor is that COHORT’s
study population is not a random sample of the general HD
population. However, it is likely representative of clinical trial
participants and thus can serve as a useful comparator for
investigations of experimental therapeutics.
Because of its large size, COHORT also provides an excellent
opportunity to examine the prevalence of individuals who have
CAG repeat lengths in the high normal range and in the range
associated with reduced penetrance. In the present study
population, 50 individuals had a larger allele in the high normal
range and an additional 50 had a shorter allele in that range. Of
these, 17 (5.1%) were among the 336 first-degree relatives who had
not pursued prior genetic testing, and 15 (5.2%) were among the
289 first-degree relatives who had pursued genetic testing prior to
the onset of HD. A previous study reported that 7% of individuals
pursuing genetic testing for HD had CAG repeat lengths in the
high normal range [26]. Together these results suggest that the
prevalence of high normal alleles among individuals at-risk for HD
is not rare. Based on modeling estimates, the likelihood that a male
high normal allele carrier will have offspring with an expanded
penetrant allele is small, on the order of one in a thousand [6,27].
Although the current COHORT sample is not sufficiently large to
test this estimate, future data linking across generations using the
Family History Questionnaire could better define the stability of
repeat lengths between generations, and longitudinal follow-up
will help to characterize the clinical evolution of these individuals.
COHORT also has 53 individuals with CAG repeat lengths
associated with reduced penetrance on their larger allele. Twenty-
five (8.7%) of the individuals without clinically diagnosed HD who
had pursued pre-symptomatic testing and 13 (3.9%) of first-degree
relatives who had not pursued genetic testing had repeat lengths
associated with reduced penetrance. These results correspond to a
recent report that 5% of individuals undergoing pre-symptomatic
Table 5. CAG repeat length of the larger Huntingtin allele in different groups in the COHORT study.
Groups that carry an expanded allele Groups that do not carry an expanded allele
Individuals with
clinically
diagnosed HD
[n=930]
First-degree
relatives who
pursued genetic
testing and carry an
expanded
allele
[n=248]
First-degree
relatives who
did not pursue
genetic testing
and carry an
expanded allele
[n=112]
First-degree
relatives who did
not pursue genetic
testing and do not
carry an expanded
allele
[n=224]
First-degree
relatives who
pursued genetic
testing and do
not carry an
expanded allele
[n=41]
Spouses
and caregivers
[n=430]
(CAG)n of 26 or less [n (%)] 0 0 0 209 (93.3) 38 (92.7) 398 (92.6)
(CAG)n between 27 and 35
(inclusive) [n (%)]
0 0 0 15 (6.7) 3 (7.3) 32 (7.4)
(CAG)n between 36 and 39
(inclusive) [n (%)]
15 (1.6) 25 (10.1) 13 (11.6) 0 0 0
(CAG)n of 40 or more [n (%)] 915 (98.4) 223 (89.9) 99 (88.4) 0 0 0
doi:10.1371/journal.pone.0029522.t005
Table 4. Three most common medication classes used by participants in the COHORT study.
Manifest HD
n=930
n
(%)
Pre-manifest
HD
n=248
n
(%)
At-risk and
carrying an
expanded
allele
n=112
n
(%)
At-risk but not
carrying an
expanded
allele
n=224
n
(%)
First degree
relatives known
not to carry an
expanded allele
n=41
n
(%)
Control
participants
(spouses and
caregivers)
n=430
n
(%)
1 Antidepressants 301
(32)
Multivitamins 65
(26)
Multivitamins 27
(24)
Multivitamins 55
(25)
Multivitamins 7
(17)
Multivitamins 135
(31)
2 Multivitamins 255
(27)
Lipid-modifying
agents
51
(21)
Antidepressants 13
(12)
Lipid-modifying
agents
39
(17)
Calcium;
Lipid-modifying agents
5
(12)
Lipid-modifying
agents
94
(22)
3 Antipsychotics 228
(25)
Antidepressants 48
(19)
Lipid-modifying
agents
10
(9)
Antiinflammatory
and antirheumatic
products;
Non-steroids
26
(12)
Combinations;
Unspecified herbals
4
(10)
Combinations* 60
(14)
*Combinations=products containing two or more active ingredients.
doi:10.1371/journal.pone.0029522.t004
COHORT Study
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In COHORT, 15 (28.3%) of these 53 individuals had received a
clinical diagnosis of HD prior to enrollment in the study. Current
estimatessuggestthatatleast40%ofindividualswitha repeat inthis
range will be asymptomatic at age 65 [4], which can be verified
through prospective assessments in COHORT.
Beyond this report, COHORT’s value lies in its potential to
serve as an open resource for HD investigators and to inform the
design and conduct of future clinical trials. The phenotypic and
genotypic data derived and the current biological specimens can
be accessed by researchers anywhere through a brief proposal
process by contacting cohort.projectmanager@ctcc.rochester.edu.
Table 6. CAG repeat length of the shorter Huntingtin allele in different groups in the COHORT study.
Groups that carry an expanded allele Groups that do not carry an expanded allele
Individuals with
clinically
diagnosed HD
[n=930]
First-degree
relatives who
pursued genetic
testing and
carry an
expanded allele
[n=248]
First-degree
relatives who
did not pursue
genetic testing
and carry an
expanded allele
[n=112]
First-degree
relatives who did
not pursue genetic
testing and do not
carry an expanded
allele
[n=224]
First-degree
relatives who
pursued genetic
testing and do
not carry an
expanded allele
[n=41]
Spouses
and
caregivers
[n=430]
(CAG)n of 26 or less [n (%)] 893 (96.0) 236 (95.2) 110 (98.2) 224 (100) 41 (100) 430 (100)
(CAG)n between 27 and 35
(inclusive) [n (%)]
36 (3.9) 12 (4.8) 2 (1.8) 0 0 0
(CAG)n between 36 and 39
(inclusive) [n (%)]
1 (0.1) 0 0 0 0 0
(CAG)n of 40 or more [n (%)] 000 0 00
COHORT=Cooperative Huntington Observational Research Trial; HD=Huntington disease; (CAG)n=cytosine-adenine-guanine trinucleotide repeat length.
doi:10.1371/journal.pone.0029522.t006
Figure 2. Distribution of the CAG repeat length of the larger Huntingtin allele for all individuals carrying an expanded allele in the
COHORT study.
doi:10.1371/journal.pone.0029522.g002
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e29522Additional genetic evaluations of the influence of non-expanded
Huntingtin CAG repeats, the GRIK2 gene [28], and other potential
genetic modifiers of HD pathogenesis are underway. Many
clinically-oriented questions remain, including a detailed longitu-
dinal history of the cardinal features of HD; factors that influence
those features; the long-term safety of approved and experimental
therapies for HD; and trends in the clinical care of those with and
at-risk for HD.
In addition to answering important research questions,
COHORT can inform and enhance the investigation of
experimental therapeutics. The selection of outcome measures
that are sensitive to changes in different features of the disease with
low variability is an important decision for clinical trials. In
addition, COHORT can be used to determine the relative
number of research participants available based on different
inclusion criteria for clinical trials. Finally, the study can and has
been used to identify potential research participants and sites for
clinical trials based on key entry criteria. For example, in a study
looking at a treatment for cognitive impairment in HD,
COHORT could be used to identify research participants with
a MMSE score below a specific threshold.
While COHORT has tremendous value and potential, it has
several limitations. The study population – overwhelmingly
white, relatively highly educated, and currently centered in
three countries – may not be representative of the broader
HD population. Study participants were enrolled primarily at
academic research centers, which might limit the generalizability
to individuals lacking access to these clinics, including those
residing in nursing facilities. A sister European study called
REGISTRY can address some of these limitations [29]. Another
limitation is that COHORT currently has few biological markers
tied to the study that can take advantage of the large and
valuable clinical dataset. Additional studies could be incorpo-
rated into COHORT to allow better coupling of phenotypic
data with the growing knowledge of biomarkers in HD [30]. Like
other large, multi-center studies, ensuring the completeness of
the clinical and genetic data captured in the study can be
difficult. For this report, we excluded data from approximately
15% of research participants principally due to incomplete
genetic data or potentially inconsistent clinical and genetic data,
which is currently under investigation. Future collection and
verification of the data over time will allow for more complete
reporting.
This report details the baseline characteristics of nearly 2000
individuals from families affected by HD, demonstrates clinical
differences and their size, and highlights over 150 individuals with
high normal or reduced penetrant Huntingtin alleles. More
importantly, this report establishes the foundation for valuable
longitudinal analyses of this population, a resource for HD
investigators globally, and a powerful tool for designing and
conducting future trials of experimental therapeutics for HD.
Supporting Information
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